Hangzhou HEDA Biological Medicine Venture Capital Partnership
Overview
Hangzhou HEDA Biological Medicine Venture Capital Partnership is a private equity institution established in 2011, primarily focusing on investments in the new energy manufacturing sector. The firm has a cumulative assets under management (AUM) of 5 billion RMB and holds equity in 45 enterprises, collectively generating annual sales of 150 billion RMB. The partnership collaborates with both domestic and international renowned investment institutions, having jointly funded and established 27 sub-funds with a total scale of 18 billion RMB. This extensive network enables HEDA to leverage diverse expertise and resources in its investment endeavors. HEDA's investment portfolio includes companies such as MINGDE Energy Storage, a firm specializing in new energy management and operations, and Lynk Pharmaceuticals, an innovative pharmaceutical R&D company. These investments reflect HEDA's commitment to supporting advancements in biotechnology, healthcare, and sustainable energy solutions.
Investment Focus
- Focus on new energy manufacturing sector
- Collaboration with domestic and international investment institutions
- Support for innovative biotechnology and healthcare companies
Portfolio Companies
Reach Hangzhou HEDA Biological Medicine Venture Capital Partnership directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Hangzhou HEDA Biological Medicine Venture Capital Partnership
What sectors does Hangzhou HEDA Biological Medicine Venture Capital Partnership invest in?
Hangzhou HEDA Biological Medicine Venture Capital Partnership invests in Healthcare, Pharmaceuticals, Medical Devices, Biotechnology, Synthetic Biology and Biopharmaceuticals, and is based in Zhejiang, China. Hangzhou HEDA Biological Medicine Venture Capital Partnership is listed as a venture capital in the ConnectSafely investor database.
What stage does Hangzhou HEDA Biological Medicine Venture Capital Partnership invest at?
Hangzhou HEDA Biological Medicine Venture Capital Partnership backs companies at Seed, Early Stage, Growth and Late Stage, writing cheques of 5M - 50M.
Which regions does Hangzhou HEDA Biological Medicine Venture Capital Partnership invest in?
Hangzhou HEDA Biological Medicine Venture Capital Partnership invests across China.
What companies has Hangzhou HEDA Biological Medicine Venture Capital Partnership invested in?
Hangzhou HEDA Biological Medicine Venture Capital Partnership's portfolio includes LYNK Pharmaceuticals and MINGDE Energy Storage.
Last updated · Source: ConnectSafely investor database
